• PARP7 Inhibition Restores STAT1/2 and Ameliorates EAE in Mic

  2026-07-24

  Xu et al. (2025) reveal that PARP7 suppresses type I interferon signaling by promoting autophagic degradation of STAT1/STAT2, leading to worsened neuroinflammation in a mouse model of multiple sclerosis. Pharmacological inhibition of PARP7 stabilizes these transcription factors and significantly alleviates experimental autoimmune encephalomyelitis (EAE), highlighting a promising immunoregulatory target for MS research.

• BI 2536: Driving Translational Precision with Selective PLK1

  2026-07-24

  This article explores how BI 2536, a highly selective PLK1 inhibitor from APExBIO, enables translational researchers to dissect mitotic control, optimize in vitro and in vivo cancer models, and refine mechanistic understanding of cell cycle G2/M arrest and apoptosis. Drawing on recent advances in in vitro drug assessment and mechanistic checkpoint research, it delivers actionable strategy for maximizing experimental rigor and translational relevance.

• Cefoperazone Sodium Salt: Applied Workflows in Antimicrobial

  2026-07-23

  Cefoperazone sodium salt stands out for its robust β-lactamase stability and broad-spectrum efficacy, making it ideal for in vitro antimicrobial activity assays and resistance modeling. This article delivers actionable protocols, troubleshooting strategies, and advanced insights to optimize your bench research using APExBIO's trusted compound.

• Nav1.5 Ser571 Phosphorylation Drives Cardiac Aging Phenotype

  2026-07-23

  This study uncovers how phosphorylation of the cardiac sodium channel Nav1.5 at Ser571 increases late sodium current (INa,L), driving delayed ventricular repolarization and diastolic dysfunction in aging hearts. The findings clarify molecular mechanisms of age-related cardiac decline and suggest late sodium current inhibition as a targeted intervention for arrhythmia prevention research.

• Olaparib (AZD2281): Precise PARP-1/2 Inhibition for Cancer R

  2026-07-22

  Olaparib (AZD2281) is a well-characterized, potent PARP-1/2 inhibitor used for DNA damage response studies and BRCA-associated cancer targeted therapy. Its mechanism exploits homologous recombination repair defects, delivering selective cytotoxicity in BRCA-mutant models. This article reviews molecular rationale, evidence benchmarks, and protocol parameters for translational and preclinical workflows.

• Heterologous Regulation Enhances A40926 and Teicoplanin Yiel

  2026-07-22

  This study investigates how introducing heterologous StrR-like regulatory genes from lipodepsipeptide biosynthetic clusters influences the production of glycopeptide antibiotics, specifically A40926 and teicoplanin. The findings reveal that certain cross-pathway regulators can boost antibiotic yields, presenting new strategies for optimizing biosynthetic output in actinobacteria.

• Linoleic Acid (C18:2) Protocols: Preparation and QC Guidance

  2026-07-21

  Linoleic Acid (C18:2(9Z,12Z); SKU C3108) is a validated reagent for modeling oxidative stress, membrane fluidity, and essential fatty acid deficiency in both cell-based and animal research. It is not suitable for water-based protocols or experiments requiring long-term solution stability, making it essential to follow precise preparation and storage practices for reproducible results.

• NU7441 (KU-57788): Precision DNA-PK Inhibition in Cancer Res

  2026-07-21

  NU7441 (KU-57788) empowers researchers with selective, nanomolar inhibition of DNA-PK, enabling precise interrogation of DNA repair and immune escape mechanisms in oncology. Its high specificity and protocol versatility make it a cornerstone for advanced DNA damage response studies and cell cycle modulation.

• CHI3L1-IN-5 (Compound Z17): Workflow-Driven Neuroinflammatio

  2026-07-20

  CHI3L1-IN-5 (Compound Z17) stands out as a dual-action small molecule for targeted modulation of neuroinflammation and restoration of amyloid-beta clearance in astrocytes. Its optimized pharmacokinetics and CNS penetration, combined with validated inhibition of CHI3L1-mediated NF-κB inflammatory signaling, deliver a robust platform for translational Alzheimer’s disease research.

• Scenario-Driven Strategies with EdU Imaging Kits (HF594)

  2026-07-20

  This article provides an evidence-based, scenario-driven guide for leveraging EdU Imaging Kits (HF594), SKU K2243, to overcome common challenges in cell proliferation and DNA synthesis assays. Drawing from current literature and validated protocols, we highlight the kit’s advantages in sensitivity, workflow integrity, and reproducibility, making it a reliable solution for demanding research workflows.

• Rifampin in Synthetic Biology: Precision Tools for Transcrip

  2026-07-19

  Explore how Rifampin, a rifamycin antibiotic, is revolutionizing transcriptional regulation studies and bacterial resistance mechanism research in synthetic biology. This article delivers advanced, evidence-based insights into its mechanism, assay strategies, and integration with next-generation gene control technologies.

• Actinomycin D in Applied Research: Protocols and Precision T

  2026-07-18

  Actinomycin D (ActD) stands as an essential tool for dissecting transcriptional dynamics, apoptosis induction, and DNA damage response, with unique value in mRNA stability and cancer model assays. This article delivers actionable workflows, troubleshooting strategies, and evidence-based optimizations—bridging recent discoveries in ferroptosis and wound healing with advanced lab applications.

• LY2109761: Dual TGF-β Receptor Inhibition in Anti-Tumor and

  2026-07-17

  Explore the advanced applications of LY2109761, a TGF-β receptor type I and II dual inhibitor, in modulating Smad2/3 signaling for tumor and fibrosis research. This article delivers unique insights into mechanistic action, protocol guidance, and translational implications that go beyond existing reviews.

• Trilaurin (Glycerol Tridodecanoate): Applied Workflows & Opt

  2026-07-17

  Trilaurin (Glycerol Tridodecanoate) delivers unique versatility as both a lipid excipient and biocatalytic substrate, enabling highly efficient workflows in drug delivery and enzymatic synthesis. This article offers stepwise protocols, evidence-backed troubleshooting, and comparative insights for researchers seeking robust, reproducible results across pharmaceutical, biochemical, and translational research domains.

• Cytosolic DNA Accumulation Regulates TDP-43 Homeostasis in A

  2026-07-16

  This study reveals that persistent cytosolic DNA accumulation drives the pathological mislocalization and phase separation of TDP-43—a process central to neurodegenerative diseases like ALS. The findings suggest a previously underappreciated link between DNA damage, nuclear envelope integrity, and TDP-43 proteinopathy, highlighting new experimental approaches for DNA repair and neurodegeneration research.

16251 records 1/1084 page Next 12345 下5页 Last page